GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 196 ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 C. Revenue from contracts with customers disaggregated based on geography Revenue from the Country of Domicile- India 3184,22.92 3206,92.12 Revenue from foreign countries 14,63.30 17,45.95 3198,86.22 3224,38.07 D. Reconciliation of gross revenue with revenue from contracts with customers Gross revenue 3401,10.24 3325,23.99 Less: Trade discounts, volume rebates, etc. 231,62.85 137,88.88 Net revenue recognised from contracts with customers 3169,47.39 3187,35.11 Note 27 : Other income Interest income on: Deposits with banks 39,00.37 65,78.56 Income Tax Refund 71,28.52 10,20.62 Loans 16.04 19.36 Others 12.56 2.01 Gain on disposal of Property, Plant and Equipment (net) - 2,33.36 Liabilities Written Back - 47.32 Miscellaneous income 0.78 0.01 110,58.27 79,01.24 Note 28 : Cost of materials consumed Cost of materials consumed 472,02.47 474,37.97 472,02.47 474,37.97 Note 29 : Changes in inventories of Finished Goods, Stock-in- Trade and Work-In-Progress Opening stock Finished goods 92,38.26 174,06.81 Stock-in-trade 280,02.46 171,54.28 Work-in-progress 30,72.62 22,08.98 403,13.34 367,70.07 Less: Closing stock Finished goods 127,87.81 92,38.26 Stock-in-trade 313,38.13 280,02.46 Work-in-progress 1,30.12 30,72.62 442,56.06 403,13.34 (39,42.72) (35,43.27)